CIDP
MCID: CHR283
MIFTS: 40

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyneuropathy

Aliases & Descriptions for Chronic Inflammatory Demyelinating Polyneuropathy:

Name: Chronic Inflammatory Demyelinating Polyneuropathy 38 50 51 56
Chronic Inflammatory Demyelinating Polyradiculoneuropathy 50 56
Cidp 50 56
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 69

Characteristics:

Orphanet epidemiological data:

56
chronic inflammatory demyelinating polyneuropathy
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Orphanet 56 ORPHA2932
UMLS via Orphanet 70 C0393819
ICD10 via Orphanet 34 G61.8

Summaries for Chronic Inflammatory Demyelinating Polyneuropathy

NIH Rare Diseases : 50 chronic inflammatory demyelinating polyneuropathy (cidp) is a neurological disorder that causes progressive weakness and impaired sensory function in the legs and arms. symptoms often include tingling or numbness (first in the toes and fingers); weakness of the arms and legs; loss of deep tendon reflexes; fatigue; and abnormal sensations. cidp is thought to be caused by the immune system mistakenly attacking and damaging the myelin sheath (protective cover of nerve fibers) of the peripheral nerves. cidp is closely related to guillain-barre syndrome (gbs) and is considered the "chronic counterpart" of gbs. treatment may include corticosteroids, immunosuppressant drugs, plasma exchange, physiotherapy, and/or intravenous immunoglobulin (ivig) therapy. left untreated, 30% of people with cidp will progress to wheelchair dependence. last updated: 2/27/2017

MalaCards based summary : Chronic Inflammatory Demyelinating Polyneuropathy, also known as chronic inflammatory demyelinating polyradiculoneuropathy, is related to chronic myelomonocytic leukemia and chronic inflammatory demyelinating polyradiculoneuropathy. An important gene associated with Chronic Inflammatory Demyelinating Polyneuropathy is AIF1 (Allograft Inflammatory Factor 1), and among its related pathways/superpathways are Cell adhesion molecules (CAMs) and Spinal Cord Injury. The drugs Antibodies and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and endothelial.

NINDS : 51 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disorder, which is sometimes called chronic relapsing polyneuropathy, is caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves. Although it can occur at any age and in both genders, CIDP is more common in young adults, and in men more so than women. It often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. CIDP is closely related to Guillain-Barre syndrome and it is considered the chronic counterpart of that acute disease.

Wikipedia : 71 Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated inflammatory... more...

Related Diseases for Chronic Inflammatory Demyelinating Polyneuropathy

Diseases in the Demyelinating Polyneuropathy family:

Chronic Inflammatory Demyelinating Polyneuropathy Subacute Inflammatory Demyelinating Polyneuropathy

Diseases related to Chronic Inflammatory Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 106)
id Related Disease Score Top Affiliating Genes
1 chronic myelomonocytic leukemia 28.4 AIF1 CNTN2 GDNF HLA-DRB1 HP TTR
2 chronic inflammatory demyelinating polyradiculoneuropathy 12.5
3 chronic inflammatory demyelinating polyneuritis 11.2
4 polyneuropathy 11.2
5 demyelinating polyneuropathy 11.2
6 polyradiculoneuropathy 11.1
7 neuropathy, inflammatory demyelinating 10.8
8 neuropathy 10.5
9 hepatitis 10.2
10 myasthenia gravis 10.1
11 charcot-marie-tooth disease 10.1
12 poems syndrome 10.1
13 tooth disease 10.1
14 melanoma 10.1
15 multifocal motor neuropathy 10.1
16 hepatitis b 10.1
17 meningeal melanoma 10.0 AIF1 TTR
18 hematocele of tunica vaginalis testis 10.0 HP TTR
19 lymphoma 10.0
20 glomerulonephritis 10.0
21 respiratory failure 10.0
22 spastic entropion 10.0 HP TTR
23 neuronitis 9.9
24 diabetic polyneuropathy 9.9
25 guillain-barre syndrome 9.9
26 arthritis 9.9
27 lupus erythematosus 9.9
28 endotheliitis 9.9
29 tuberculosis 9.9
30 psoriasis 9.9
31 systemic lupus erythematosus 9.9
32 myopathy 9.9
33 intracranial hypertension 9.9
34 crohn's disease 9.9
35 scoliosis 9.9
36 diabetic neuropathy 9.9
37 mononeuritis multiplex 9.9
38 amyloid neuropathy 9.9
39 focal segmental glomerulosclerosis 9.9
40 hepatitis c 9.9
41 charcot-marie-tooth disease, type 1a 9.9
42 penis agenesis 9.9 HLA-DRB1 TTR
43 endogenous depression 9.9 HLA-DRB1 HP
44 focal epithelial hyperplasia 9.9 HP TTR
45 periarthritis 9.9 HLA-DRB1 HP
46 choreatic disease 9.8 HLA-DRB1 HP
47 trigeminal neuralgia 9.8
48 mononeuropathy 9.8
49 dermatitis 9.8
50 dysautonomia 9.8

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyneuropathy:



Diseases related to Chronic Inflammatory Demyelinating Polyneuropathy

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyneuropathy

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy

Drugs for Chronic Inflammatory Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
2 gamma-Globulins Phase 4,Phase 3,Phase 2
3 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
4 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2
5 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2
6
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
7
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
8
Mycophenolic acid Approved Phase 3 24280-93-1 446541
9
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
10
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
11 tannic acid Approved, Nutraceutical Phase 3
12 Immunoglobulin G Phase 3
13 Fingolimod Hydrochloride Phase 3
14 Immunosuppressive Agents Phase 3,Phase 2
15 Anti-Inflammatory Agents Phase 3
16 Antineoplastic Agents, Hormonal Phase 3
17 glucocorticoids Phase 3
18 Hormone Antagonists Phase 3,Phase 2
19 Hormones Phase 3,Phase 2
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
21 3,4-diaminopyridine Phase 3
22 Potassium Channel Blockers Phase 3
23 Pharmaceutical Solutions Phase 3,Phase 2
24 Anti-Bacterial Agents Phase 3
25 Antibiotics, Antitubercular Phase 3
26
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
28 Antioxidants Phase 2
29 Micronutrients Phase 2
30 Protective Agents Phase 2
31 Thioctic Acid Phase 2
32 Trace Elements Phase 2
33 Vitamin B Complex Phase 2
34 Vitamins Phase 2
35 Adjuvants, Immunologic Phase 2
36 Anti-Infective Agents Phase 2
37 Antiviral Agents Phase 2
38 Interferon-beta Phase 2
39 interferons Phase 2
40 Alpha-lipoic Acid Nutraceutical Phase 2
41 Folate Nutraceutical Phase 2
42 Vitamin B9 Nutraceutical Phase 2
43 Antibodies, Anti-Idiotypic

Interventional clinical trials:

(show all 42)
id Name Status NCT ID Phase
1 IVIg for Demyelination in Diabetes Mellitus Recruiting NCT02372149 Phase 4
2 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4
3 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3
4 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
6 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3
7 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3
8 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3
9 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3
10 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3
11 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3
12 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
13 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
14 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Recruiting NCT02293460 Phase 3
15 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Recruiting NCT02317562 Phase 3
16 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Active, not recruiting NCT02027701 Phase 3
17 Interest of Mycophenolate for CIDP Weaning Active, not recruiting NCT02494505 Phase 3
18 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3
19 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Not yet recruiting NCT02638207 Phase 3
20 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3
21 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2
22 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2
23 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2
24 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2
25 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Recruiting NCT02282514 Phase 1, Phase 2
26 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Recruiting NCT02967679 Phase 1, Phase 2
27 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
28 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2
29 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2
30 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
31 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678
32 MRI in Diagnosing and Monitoring CIDP Completed NCT02017769
33 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590
34 Study of CIDP Patients During IVIG Treatment Completed NCT00305266
35 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
36 Subcutaneous Immunoglobulin for CIDP Recruiting NCT02465359
37 IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements Recruiting NCT02414490
38 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Recruiting NCT02271724
39 Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Recruiting NCT02629796
40 Transcriptome Analysis of the Peripheral Blood in CIDP Recruiting NCT02404298
41 Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin Not yet recruiting NCT02892890
42 Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuro Not yet recruiting NCT03008733

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyneuropathy

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Chronic Inflammatory Demyelinating Polyneuropathy:
Hematopoietic stem cells for treatment of chronic inflammatory demyelinating polyneuropathy
Embryonic/Adult Cultured Cells Related to Chronic Inflammatory Demyelinating Polyneuropathy:
Bone marrow-derived hematopoietic stem cells PMIDs: 17277794

Genetic Tests for Chronic Inflammatory Demyelinating Polyneuropathy

Anatomical Context for Chronic Inflammatory Demyelinating Polyneuropathy

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyneuropathy:

39
T Cells, Bone, Endothelial, Skin, B Cells, Spinal Cord, Thyroid

Publications for Chronic Inflammatory Demyelinating Polyneuropathy

Articles related to Chronic Inflammatory Demyelinating Polyneuropathy:

(show top 50) (show all 521)
id Title Authors Year
1
Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. ( 28000311 )
2017
2
Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with antineurofascin-155 and anticontactin-1 antibodies. ( 28073817 )
2017
3
Postural tremor and chronic inflammatory demyelinating polyneuropathy. ( 27421831 )
2016
4
Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. ( 26843559 )
2016
5
Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. ( 27401495 )
2016
6
Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy. ( 26900579 )
2016
7
Challenges in pediatric chronic inflammatory demyelinating polyneuropathy. ( 27793469 )
2016
8
Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection: A case report. ( 27930572 )
2016
9
Poster 487 Chronic Inflammatory Demyelinating Polyneuropathy or Something Else?: A Case Report. ( 27673228 )
2016
10
The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. ( 27389526 )
2016
11
Evaluation of Patients with Refractory Chronic Inflammatory Demyelinating Polyneuropathy. ( 27463215 )
2016
12
Intrathecal Dexmedetomidine for Anaesthetic Management of a Patient with Chronic Inflammatory Demyelinating Polyneuropathy. ( 27790558 )
2016
13
Anti-ganglioside antibodies in Guillain-BarrAc syndrome and chronic inflammatory demyelinating polyneuropathy in Chinese patients. ( 27464289 )
2016
14
Chronic inflammatory demyelinating polyneuropathy variant (Lewis- Sumner syndrome) in HIV. ( 27727849 )
2016
15
Poster 373-A Immunoglobulin Treatment of Miller Fisher Variant of Acute Demyelinating Inflammatory Polyneuropathy with Underlying Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. ( 27673265 )
2016
16
NADPH oxidase 2 (NOX2) enzyme activation in patients with chronic inflammatory demyelinating polyneuropathy. ( 26924156 )
2016
17
Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-Neurofascin 155 antibodies. ( 27986399 )
2016
18
Loss of Schwann cell plasticity in chronic inflammatory demyelinating polyneuropathy (CIDP). ( 27677703 )
2016
19
Novel Therapeutic Avenues for Chronic Inflammatory Demyelinating Polyneuropathy: The Difficulties of Disease Diversity. ( 27211536 )
2016
20
Complete neurologic and cognitive recovery after plasmapheresis in a patient with chronic inflammatory demyelinating polyneuropathy after allogeneic hematopoietic stem cell transplantation. ( 26919852 )
2016
21
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. ( 27455854 )
2016
22
Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy. ( 26809024 )
2016
23
Chronic inflammatory demyelinating polyneuropathy associated with Rickettsia conorii: First case report. ( 27871450 )
2016
24
Poster 353 Acute Onset Chronic Inflammatory Demyelinating Polyneuropathy (A-CIDP) with CNS Involvement Initially Diagnosed as Guillain-Barre Syndrome (GBS): A Case Report. ( 27673107 )
2016
25
The electrophysiological response to immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. ( 27546708 )
2016
26
A case of intravenous immunoglobulin-dependent chronic inflammatory demyelinating polyneuropathy of pure motor form responsive to mycophenolate mofetil therapy. ( 27680225 )
2016
27
Incidence and Natural History of Idiopathic Chronic Inflammatory Demyelinating Polyneuropathy: A Population-Based Study in Iceland. ( 27211228 )
2016
28
Diffusion tensor imaging can be used to detect lesions in peripheral nerves in patients with chronic inflammatory demyelinating polyneuropathy treated with subcutaneous immunoglobulin. ( 27114080 )
2016
29
Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-I+ Therapy With Infliximab for Crohn's Disease. ( 27144200 )
2016
30
Evaluation of chronic inflammatory demyelinating polyneuropathy: 3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI). ( 27208993 )
2016
31
Electrophysiological and neuromuscular stability of persons with chronic inflammatory demyelinating polyneuropathy (CIDP). ( 27997686 )
2016
32
Chronic inflammatory demyelinating polyneuropathy associated with manic symptoms. ( 27571998 )
2016
33
Disease activity in chronic inflammatory demyelinating polyneuropathy. ( 27653889 )
2016
34
The development of chronic inflammatory demyelinating polyneuropathy during adalimumab treatment in a patient with psoriasis vulgaris. ( 27086491 )
2016
35
Poster 11 A Rare Case of Chronic Inflammatory Demyelinating Polyneuropathy in the Setting of SLE: A Case Report. ( 27672778 )
2016
36
Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy. ( 25814494 )
2015
37
Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. ( 25976871 )
2015
38
Conducting processes in simulated chronic inflammatory demyelinating polyneuropathy at 20A^C-42A^C. ( 25597276 )
2015
39
Dramatic Improvement of Chronic Inflammatory Demyelinating Polyneuropathy Through Tenofovir Treatment in a Patient Infected with Hepatitis B Virus. ( 25850895 )
2015
40
Chronic inflammatory demyelinating polyneuropathy associated with neurosyphilis. ( 25470500 )
2015
41
Treatment of pediatric chronic inflammatory demyelinating polyneuropathy: Challenges, controversies and questions. ( 26425012 )
2015
42
Acute-Onset chronic inflammatory demyelinating polyneuropathy. An electrodiagnostic study. ( 25809534 )
2015
43
Diagnostic criteria of chronic inflammatory demyelinating polyneuropathy in diabetes mellitus. ( 25819084 )
2015
44
Autoantibodies against vinculin in patients with chronic inflammatory demyelinating polyneuropathy. ( 26439954 )
2015
45
Electrotonic potentials in simulated chronic inflammatory demyelinating polyneuropathy at 20A^C-42A^C. ( 25916252 )
2015
46
Treatment of chronic inflammatory demyelinating polyneuropathy. ( 26008811 )
2015
47
Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins. ( 26268846 )
2015
48
A case of chronic inflammatory demyelinating polyneuropathy with reversible alternating diaphragmatic paralysis: case study. ( 26490681 )
2015
49
Recurrent Isolated Sixth Nerve Palsy in Relapsing-Remitting Chronic Inflammatory Demyelinating Polyneuropathy. ( 26301375 )
2015
50
Chronic inflammatory demyelinating polyneuropathy with membranous nephropathy. ( 25977098 )
2015

Variations for Chronic Inflammatory Demyelinating Polyneuropathy

Expression for Chronic Inflammatory Demyelinating Polyneuropathy

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyneuropathy.

Pathways for Chronic Inflammatory Demyelinating Polyneuropathy

Pathways related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.32 CNTN2 HLA-DRB1
2 11.03 AIF1 GDNF
3 10.19 CNTN2 GDNF

GO Terms for Chronic Inflammatory Demyelinating Polyneuropathy

Biological processes related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuron projection development GO:0031175 8.62 CNTN2 GDNF

Sources for Chronic Inflammatory Demyelinating Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....